medwireNews: Two doses of depemokimab over a year can significantly reduce the risk for severe asthma exacerbations compared with placebo, show findings from the SWIFT-1/2 phase 3a trials.
11-09-2024 | Bronchial Asthma | News
11-09-2024 | Bronchial Asthma | News
medwireNews: Two doses of depemokimab over a year can significantly reduce the risk for severe asthma exacerbations compared with placebo, show findings from the SWIFT-1/2 phase 3a trials.